Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.32 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25296298 | 0.83 | AURKA (0.34) | AURKAKCNN4KCNA3MEN1SLC22A1 | |
| SCHEMBL30228734 | 0.83 | AURKA (0.34) | AURKAKCNN4KCNA3MEN1SLC22A1 | |
| SCHEMBL875874 | 0.83 | AURKA (0.34) | AURKAKCNN4KCNA3MEN1SLC22A1 | |
| SCHEMBL13060930 | 0.83 | CYP11B1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL875386 | 0.80 | MAPK1 (0.37) | MAPK1RAB9A | |
| SCHEMBL31409600 | 0.80 | AURKA (0.32) | AURKAKCNN4KCNA3 | |
| SCHEMBL24168712 | 0.79 | MAPK1 (0.32) | AURKAMAPK1 | |
| SCHEMBL875346 | 0.78 | LRRK2 (0.35) | MEN1SLC6A2MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL2630740 | 0.77 | LMNA (0.34) | LMNAMAPTHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL875603 | 0.77 | LRRK2 (0.36) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025026997-A1 | SUBSTITUED BICYCLIC HETEROCYCLIC YAP-TEAD AND/OR TAZ-TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2025-02-06 | — | — | WO | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20140288043-A1 | PYRAZOLOPYRIDINE COMPOUNDS | GENENTECH, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
| EP-2408772-A1 | COMPOUNDS | Medical Research Council Technology (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| WO-2010106333-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010106333-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | AURKA 2277/4885KCNN4 4164/4885KCNA3 3912/4885 |
| US-20140288043-A1 | PYRAZOLOPYRIDINE COMPOUNDS | KCNJ11, P2RX4, P2RY4 | AURKA 1595/4885KCNN4 96/4885KCNA3 51/4885 |
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | AURKA 1004/4885KCNN4 685/4885KCNA3 143/4885 |
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | AURKA 2750/4885KCNN4 1091/4885KCNA3 542/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | AURKA 2277/4885KCNN4 4164/4885KCNA3 3912/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | AURKA 2786/4885KCNN4 1156/4885KCNA3 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.